id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-P-1633-0006,FDA,FDA-2020-P-1633,Final Response Letter from FDA CBER to Foley Hoag LLP on behalf of the Microbiome Therapeutics Innovation Group,Other,Letter(s),2022-11-29T05:00:00Z,2022,11,2022-11-29T05:00:00Z,,2022-11-29T21:10:28Z,,0,0,0900006485509160